TY - JOUR
T1 - Differences in aggressive treatments during the actively dying phase in patients with cancer and heart disease
T2 - an exploratory study using the sampling dataset of the National Database of Health Insurance Claims
AU - Mizuno, Atsushi
AU - Miyashita, Mitsunori
AU - Ohde, Sachiko
AU - Takahashi, Osamu
AU - Yamauchi, Sayoko
AU - Nakazawa, Hitonari
AU - Komiyama, Nobuyuki
N1 - Funding Information:
This research is supported by the “Practical Research Project for Lifestyle-related Diseases including Cardiovascular Diseases and Diabetes Mellitus” from the Japan Agency for Medical Research and Development (AMED). There are no conflicts of interest to declare. The authors are grateful to Mr. Sadanobu Yamakawa, an IT Consultant at Denno Labo Corporation, and Dr. Shosuke Ohtera, Dr. Michi Sakai, and Dr. Takeo Nakayama at Kyoto University for giving us advice on setting up the sampling dataset analysis room.
Publisher Copyright:
© 2021, Springer Japan KK, part of Springer Nature.
PY - 2021/5
Y1 - 2021/5
N2 - Despite the recent attention given to palliative care for patients with heart disease, data about the treatments in their actively dying phase are not sufficiently elaborated. In this study, we used the sampling dataset of a national database to compare the aggressive treatments performed in patients with cancer and those with heart disease. We only included patients deceased in January or July from 2011 to 2015, using the Diagnosis Procedure Combination sampling dataset of the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB). Patients who were discharged within the first 10 days of each month were excluded. We explored and compared aggressive treatments such as cardiopulmonary resuscitation and intensive care utilization, performed within seven days before death in cancer patients. We used 10,637 (0.4% of the dataset) deceased target population (40.0% female), with 7844 (73.7%) and 2793 (26.3%) being the proportion of cancer and heart disease patients, respectively. Aggressive treatments and procedures such as cardiopulmonary resuscitation (18.4%), intensive care utilization (5.4%), use of inotropes (43.4%), use of respirators (29.1%), and dialysis (4.5%) were frequently observed in heart disease patients. These associations remained after adjusting for age, sex, and disease severity. This study indicates the possible use of an NDB sampling dataset to evaluate the aggressive treatments and procedures in the actively dying phase in both heart disease and cancer patients. Our results showed the differences in aggressive treatment strategies in the actively dying phase between patients with cancer and those with heart disease.
AB - Despite the recent attention given to palliative care for patients with heart disease, data about the treatments in their actively dying phase are not sufficiently elaborated. In this study, we used the sampling dataset of a national database to compare the aggressive treatments performed in patients with cancer and those with heart disease. We only included patients deceased in January or July from 2011 to 2015, using the Diagnosis Procedure Combination sampling dataset of the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB). Patients who were discharged within the first 10 days of each month were excluded. We explored and compared aggressive treatments such as cardiopulmonary resuscitation and intensive care utilization, performed within seven days before death in cancer patients. We used 10,637 (0.4% of the dataset) deceased target population (40.0% female), with 7844 (73.7%) and 2793 (26.3%) being the proportion of cancer and heart disease patients, respectively. Aggressive treatments and procedures such as cardiopulmonary resuscitation (18.4%), intensive care utilization (5.4%), use of inotropes (43.4%), use of respirators (29.1%), and dialysis (4.5%) were frequently observed in heart disease patients. These associations remained after adjusting for age, sex, and disease severity. This study indicates the possible use of an NDB sampling dataset to evaluate the aggressive treatments and procedures in the actively dying phase in both heart disease and cancer patients. Our results showed the differences in aggressive treatment strategies in the actively dying phase between patients with cancer and those with heart disease.
KW - Acute cardiovascular diseases
KW - End-of-life
KW - Heart failure
KW - Palliative care
KW - Quality indicators
UR - http://www.scopus.com/inward/record.url?scp=85099005595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099005595&partnerID=8YFLogxK
U2 - 10.1007/s00380-020-01734-6
DO - 10.1007/s00380-020-01734-6
M3 - Article
C2 - 33399899
AN - SCOPUS:85099005595
SN - 0910-8327
VL - 36
SP - 724
EP - 730
JO - Heart and Vessels
JF - Heart and Vessels
IS - 5
ER -